Friday, March 25, 2016

India - IoT - Products and Software Production and Sales



March 2016

23 March
Smartron  set to launch a slew of smart devices and Internet of Things (IoT) products for consumer and enterprise markets in the first quarter of 2016-17.  Smartron is headed by founder chairman Mahesh Lingareddy, co-founder and CEO of Soft Machines Inc, a United States based semiconductor company with operations in the US, India and Russia. It has research and development centres in Hyderabad and Bengaluru. Smartron will work in the areas of smart, sensor, robotics, artificial intelligence, cloud and big data technologies to bring next generation smart devices, services and care in consumer and industrial sector.
http://economictimes.indiatimes.com/tech/internet/sachin-tendulkar-invests-in-iot-firm-smartron-india/articleshow/51510078.cms

Sunday, February 21, 2016

World’s cheapest smartphone named Freedom 251 in India



The Ringing bell freedom 251 is a smart phone with a quad-core processor, 1GB RAM, Android lollipop 5.1 and 8GB internal storage. It  is available for Rs. 251.


Freedom 251 bookings will be open on 18th of February at 6 am and close on 21st of February at 8 pm. Deliveries will be completed by 30th of June 2016.

www.freedom251.com
www.ringingbells.co.in

The smartphone Freedom 251 comes with a 1-year warranty, 6 months for Battery and Charger and also 3 months for Earphone commencing from the date of purchase.

Official Details of Ringing bells Company:

Official Website- www.ringingbells.co.in

Registered Office address- B-44, Sector 63, Noida – 201301

Contact numbers- 08822232323, 01204313087

Official E-mail- info@ringingbells.co.in


Both Economic Times and Times of India carried news items on this smart phone. They expressed doubt on how the company can supply at this low price. The other manufacturers request Ministry of Electronics to investigate and find out if there is any foul play in the offer.


Strategy to Sell Freedom Smart Phone at Rs. 251


How will the company manage to sell it at that price?

Ringing Bell claims it will be able to achieve this feat through four strategies.

Rs 2,500, is present cost of the device.

One, the benefit excise duty cuts by assembling handsets domestically would be Rs 400 or 16 per cent of Rs 2,500.

However, they are expecting from the government, which is at 13.8 per cent or Rs 55 lower than Rs 400.


Two, as it starts manufacturing in huge quantities (at least 500,000 units a month), it would be able to cut costs by a further Rs 500 a unit.

Three, online sales will help it cut costs by another Rs 500.

Four, it will have a specialised online platform, and earn additional revenue which is going fund the sasles of Freedom 251.

(http://www.rediff.com/business/report/alarm-bells-over-rs-251-smartphone-offer/20160219.htm)



21 Feb 2016

7.35 Crore Freedom 251 Phone Booked.
30,000 persons paid the full amount.
The company owner claimed that he will get the phone made at Rs. 220.  Shipping charges are collected separately. So there is margin for him. The present market price of the phone is Rs. 1719. But they decided the pricing because they wanted India to become Digital India Country
http://www.msn.com/en-in/news/techandscience/freedom-251-booking-closed-company-to-deliver-735-cr-phones-in-2016/ar-BBpJCzX?ocid=SK2MDHP



2017

The product got into problems and the whole sales campaign became a fiasco. Its present status is to be ascertained.


Updated 21 Feb 2016,  20 Feb 2016,  17 Feb 2016


Saturday, January 30, 2016

Saturday, January 2, 2016

Monoclonal Antibodies in India

mAbs in India


Biocon was the first Indian company to come up with its mAbs product, BIOMAb-EGFR (Nimotuzumab). The product was granted regulatory marketing and manufacturing approval in India in September 2006. The product is a therapeutic monoclonal antibody-based drug for treating solid tumors of epithelial origin, such as head and neck cancers.



 “In 2007, Dr Reddy's Labs came out with the novel concept of producing the biosimilar version of Rituximab, a version of Roche's cancer therapy, which could allow a greater access to the drug at half the price of the original. Reditux is the second product from Dr Reddy's Biologics Division, which is developing treatments for cancer and autoimmune diseases. The company has also launched the generic version of Amgen's Neupogen, and named it Grafeel.

Pune-based Serum Institute has entered into another agreement with Akorn of the US in 2007  for definitive development and exclusive distribution rights for rabies mAb.

Intas Biopharmaceuticals has signed a Memorandum of Understanding (MoU) with Government of Gujarat in 2009 for setting up a separate manufacturing facility for MAbs, a recombinant mammalian platform product. The company will invest Rs 160 crore towards setting up a manufacturing facility at Sanand near Ahmedabad. The facility, fully-dedicated for mAbs, will undertake large-scale manufacturing of the recombinant product with a capacity of 5000L in phases.

 Daftary group promoted Bharat Serums and Vaccines and Bangalore-based Avesthagen are some of the other notable companies that have chalked our serious plans for mABs.



“MAbs business involves patents and for navigating through these patents requires skills,”

Future prospects
By 2015 ,  the sales of mAbs is expected to reach Rs 3 lakh crore ($67.6 bn), with a CAGR of 13.8 percent between 2008 and 2015. The biotherapeutic market would be dominated with mAbs in next five years as most of the blockbuster molecules are going off-patented.

All the pharma majors have mAbs projects in their R&D portfolio. Introduction of newer monoclonal antibodies will greatly expand the market. Globally, the FDA had approved four new mAbs and EMA had approved seven new mAbs in 2009. There were at least six new mAbs under regulatory review, 26 mAbs (32 in 2008) are in phase III and over 100 are in phase II clinical trials. There are more than 150 mAbs molecule awaiting regulatory approval. I



Compared to India, China is a big market for mAbs. Some notable  companies include Union Stem Cell and Gene Engineering and Biotech pharmaceutical. In a serious effort towards innovation,China is moving towards areas like stem cells, mAbs, cancer and HIV development and vaccines with investments being pumped in both by the Government and foreign sources.

http://www.biospectrumindia.com/biospecindia/news/157328/monoclonal-antibodies-a-profitable-segment

Monday, April 20, 2015

RTA-70 - A 70 Seater Regional Transport Plane - Development in India



2008

CSIR approved Rs. 300 cr for development of RTA-70. Prototype was expected in 2013.
http://www.nal.res.in/pdf/rtaIAfeb10.pdf


2009

India’s first attempt at certifying a regional aircraft yielded the 14-seat coastal surveillance and transport training pusher turboprop called the Saras, development of which stalled following a crash in 2009.

NAL’s attempt to develop  India’s  Light Transport Aircraft, renamed Saras in 1993, started as an Indo-Russian joint venture in 1986.  But JV partner Ilyushin withdrew from the project. Two Saras prototypes were  produced. The second prototype crashed in March 2009 during a flight test, killing all three crew members.


2010
http://www.nal.res.in/pdf/rtaIAfeb10.pdf

2013

India continues with RTA-70
http://www.ainonline.com/aviation-news/2013-07-15/india-commits-new-transport-aircraft


2014
http://www.business-standard.com/article/companies/india-s-civilian-aircraft-project-to-get-a-leg-up-114071500985_1.html

http://www.thehindubusinessline.com/economy/import-substitution-tax-sops-vital-for-aerospace-progress/article6708691.ece


2015

Aeronautical society of India News April 2015
http://www.aerosocietyindia.in/e-news/volume9/April%202015.pdf

http://defence.pk/threads/hal-nal-regional-transport-aircraft-rta-indias-regional-airliner-programme.358046/page-2

http://www.newindianexpress.com/business/news/HAL-to-Go-Ahead-with-Civil-Aircraft-Development-Project/2015/02/07/article2656716.ece